Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cimerli Success Drives Strong H1 At Formycon

Company Anticipates Highest Revenue In Its History Over Subsequent Quarters

Executive Summary

Formycon delivered a strong H1, as its Lucentis biosimilar made significant strides in the US market. The company now anticipates the highest revenue in its history for 2023.

You may also be interested in...

Formycon Gets Date For Aflibercept Filing In US

Formycon has announced a June 2024 FDA action date for its FYB203 proposed aflibercept biosimilar rival to Eylea, which is due to be marketed by Coherus in the US.

Another US Stelara Settlement Arrives, This Time For Fresenius And Formycon

A third settlement has been struck allowing a Stelara biosimilar to hit the US market in 2025, with partners Fresenius and Formycon agreeing terms with Johnson & Johnson that offer a launch date slightly later than previous settlers.

Formycon Strengthens Biosimilars Portfolio With Athos Assets

Formycon and Athos have merged aspects of their biosimilar development activities as part of a long-term strategic partnership.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts